TY - JOUR
T1 - Potential role of Howell−Jolly bodies in identifying functional hyposplenism
T2 - a prospective single-institute study
AU - Nakagami, Yuya
AU - Uchino, Kaori
AU - Okada, Hiroaki
AU - Suzuki, Kojiro
AU - Enomoto, Megumi
AU - Mizuno, Shohei
AU - Yamamoto, Hidesuke
AU - Hanamura, Ichiro
AU - Nakayama, Takayuki
AU - Tani, Hiroya
AU - Takami, Akiyoshi
N1 - Funding Information:
This study was supported by Grants from the Ministry of Education, Culture, Sports and Technology of Japan (#18K08343), the Ministry of Health, Labour and Welfare of Japan, and Sysmex Corporation. The funders played no role in the study design, data collection and analysis, the decision to publish or the preparation of the manuscript. Acknowledgements
Funding Information:
We thank all of the members of Department of Clinical Laboratory, Aichi Medical University Hospital for performing routine microscopic examinations and all of the medical staff of Aichi Medical University Hospital who provided valuable assistance in caring for the patients in this study.
Publisher Copyright:
© 2020, Japanese Society of Hematology.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Although patients with cancer and immunosuppression are at a risk of functional hyposplenism, how to detect it promptly remains unclear. Since hyposplenism allows erythrocytes with nuclear remnants (Howell−Jolly bodies [HJBs]) to appear in the peripheral blood, HJB detection by a routine microscopic examination may help identify patients with functional hyposplenism. This prospective study was thus performed to determine the underlying diseases in patients who presented with HJBs. Of 100 consecutive patients presenting with HJBs, 73 had a history of splenectomy. The remaining 27 had hematologic cancer (n = 6, 22%), non-hematologic cancer (n = 8, 30%), hepatic disorders (n = 4, 15%), premature neonates (n = 3, 11%), hemolytic anemia (n = 2, 7%), autoimmune disorders (n = 2, 7%) and miscellaneous diseases (n = 2, 7%), and their prior treatments included chemotherapy (n = 8, 30%), steroids (n = 7, 26%) and molecular-targeted therapy (n = 3, 11%). Among the 27 patients, 22 had computed tomography scans available: 3 (14%) had underlying diseases in the spleen, and the remaining 19 (86%) were all found to have a decreased splenic volume, including 11 (50%) with more than 50% of the ideal value. The present findings suggest that HJB detection identifies patients with potentially functional hyposplenism who should receive appropriate interventional treatment, such as vaccination and prophylactic antibiotics.
AB - Although patients with cancer and immunosuppression are at a risk of functional hyposplenism, how to detect it promptly remains unclear. Since hyposplenism allows erythrocytes with nuclear remnants (Howell−Jolly bodies [HJBs]) to appear in the peripheral blood, HJB detection by a routine microscopic examination may help identify patients with functional hyposplenism. This prospective study was thus performed to determine the underlying diseases in patients who presented with HJBs. Of 100 consecutive patients presenting with HJBs, 73 had a history of splenectomy. The remaining 27 had hematologic cancer (n = 6, 22%), non-hematologic cancer (n = 8, 30%), hepatic disorders (n = 4, 15%), premature neonates (n = 3, 11%), hemolytic anemia (n = 2, 7%), autoimmune disorders (n = 2, 7%) and miscellaneous diseases (n = 2, 7%), and their prior treatments included chemotherapy (n = 8, 30%), steroids (n = 7, 26%) and molecular-targeted therapy (n = 3, 11%). Among the 27 patients, 22 had computed tomography scans available: 3 (14%) had underlying diseases in the spleen, and the remaining 19 (86%) were all found to have a decreased splenic volume, including 11 (50%) with more than 50% of the ideal value. The present findings suggest that HJB detection identifies patients with potentially functional hyposplenism who should receive appropriate interventional treatment, such as vaccination and prophylactic antibiotics.
KW - Functional hyposplenism
KW - Howell−Jolly body
KW - Peripheral blood smear
UR - http://www.scopus.com/inward/record.url?scp=85086779740&partnerID=8YFLogxK
U2 - 10.1007/s12185-020-02925-7
DO - 10.1007/s12185-020-02925-7
M3 - Article
C2 - 32572828
AN - SCOPUS:85086779740
SN - 0925-5710
VL - 112
SP - 544
EP - 552
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 4
ER -